Literature DB >> 11865141

Axonal multifocal motor neuropathy without conduction block or other features of demyelination.

J S Katz1, R J Barohn, S Kojan, G I Wolfe, S P Nations, D S Saperstein, A A Amato.   

Abstract

BACKGROUND: Conduction block is considered an essential finding for the distinction between motor neuropathies and lower motor neuron disorders. Only a small number of reports describe patients with multifocal motor neuropathies who lack overt conduction block, although in these cases other features of demyelination still suggest the presence of a demyelinating disorder. In contrast, a purely axonal multifocal motor neuropathy has not been described.
METHODS: This report describes nine patients with slowly or nonprogressive multifocal motor neuropathies who had purely axonal electrodiagnostic features.
RESULTS: GM1 antibodies titers were normal in all nine cases. Six patients were treated with either prednisone or IV immunoglobulin and three showed convincing improvement.
CONCLUSIONS: These findings suggest an immune-mediated motor neuropathy with axonal electrophysiologic features that appears to be distinct from both multifocal motor neuropathy and established motor neuron disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865141     DOI: 10.1212/wnl.58.4.615

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  MR neurography findings in axonal multifocal motor neuropathy.

Authors:  Chiara Briani; Mario Cacciavillani; Marta Lucchetta; Diego Cecchin; Roberto Gasparotti
Journal:  J Neurol       Date:  2013-07-28       Impact factor: 4.849

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

3.  On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy.

Authors:  Dirk Fischer; Christoph Grothe; Stephan Schmidt; Rolf Schröder
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block?

Authors:  Neil G Simon; Gretchen Ayer; Catherine Lomen-Hoerth
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

Review 5.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

6.  P-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptoms.

Authors:  Steven A Greenberg
Journal:  BMC Neurol       Date:  2002-10-31       Impact factor: 2.474

Review 7.  Differentiating lower motor neuron syndromes.

Authors:  Nidhi Garg; Susanna B Park; Steve Vucic; Con Yiannikas; Judy Spies; James Howells; William Huynh; José M Matamala; Arun V Krishnan; John D Pollard; David R Cornblath; Mary M Reilly; Matthew C Kiernan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-12-21       Impact factor: 10.154

Review 8.  Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy study.

Authors:  Todd D Levine; Jonathan S Katz; Richard Barohn; Leslie J Vaughan; Mazen M Dimachkie; David S Saperstein; Tahseen Mozaffar; Gil I Wolfe; Matthew S Mayo; Gary J Badger; Lara Katzin; Elissa Ritt; Michelle Greer; Joseph DiStefano; Patrick M Schmidt
Journal:  Neurol Clin Pract       Date:  2018-10

9.  CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy.

Authors:  Takahiro Furukawa; Naoko Matsui; Koji Fujita; Hiroyuki Nodera; Fumitaka Shimizu; Katsuichi Miyamoto; Yukitoshi Takahashi; Takashi Kanda; Susumu Kusunoki; Yuishin Izumi; Ryuji Kaji
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-08-06

Review 10.  Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.

Authors:  Victoria H Lawson; W David Arnold
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-05       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.